Researchers discovered a link between circadian clock disturbances in pancreatic cells and type 2 diabetes (T2D), according a study published in Proceedings of the National Academy of Sciences.
Researchers discovered a link between circadian clock disturbances in pancreatic cells and type 2 diabetes (T2D), according a study published in Proceedings of the National Academy of Sciences.
Disturbances like time zone changes, irregular work schedules, and aging can prevent correct functioning of cells that secrete insulin and glucagon in the pancreatic islet; researchers came to this conclusion by comparing pancreatic cells of T2D organ donors with cells in healthy controls. To do so, they used “combined bioluminescence-fluorescence time-lapse microscopy, a technology that allows tracking the molecular clock activity in living cells very precisely over time.”
This marks the first time anyone has demonstrated “the pancreatic islet cells derived from the T2D human donors bear compromised circadian oscillators. The disruption of the circadian clocks was concomitant with the perturbation of hormone secretion.”
The study also proved a clock modulator molecule extracted from a lemon peel, labeled Nobiletin, is effective in repairing disrupted cellular clocks and partially restoring islet cell function.
“Nobiletin, an agonist of the core-clock proteins RORα/γ, boosted both circadian amplitude of T2D islet clocks and insulin secretion by these islets,” researchers said. They continued, “Our study emphasizes a link between the circadian clockwork and T2D and proposes that clock modulators hold promise as putative therapeutic agents” for patients with T2D.
Additional findings include:
An author of the study, Charna Dibner, PhD, explained, “Our society experiences epidemic growth in metabolic diseases, concomitant with shifted working and eating schedules, and lack of sleep.” She continued, “By re-synchronizing the perturbed molecular clocks, either by personalized eating and exercise schedules or with the help of clock modulator molecules, we hope to ultimately be able to provide an innovative solution to an epidemical metabolic problem affecting an ever-increasing proportion of the world's population.”
Reference:
Petrenko V, Gandasi NR, Sage D, et al. In pancreatic islets from type 2 diabetes patients, the dampened circadian oscillators lead to reduced insulin and glucagon exocytosis [published online January 21, 2020]. Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1916539117.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More